Exosomes Next-Generation Approaches in Breast Cancer: Nano Drug Delivery to AI-Based Prediction
Abstract
Exosome mimetic nanocarriers have risen as a progressive biomimetic approach for intracellular drug delivery, exploiting the unique properties of natural exosomes to enhance therapeutic precision and efficacy. These synthetic vesicles imitate the structural, biochemical, and functional characteristics of natural exosomes, including lipid bilayer composition, surface proteins, and molecular cargo, offering superior biocompatibility, immune evasion, and targeted delivery capabilities. Unlike traditional nanocarriers, exosome mimetics exploit receptor-mediated endocytosis and natural cellular communication pathways to facilitate efficient intracellular transport and controlled release of therapeutic payloads such as chemotherapeutic agents, nucleic acids(siRNA, miRNA, mRNA) and proteins. Engineering strategies combine advanced liposome technologies with exosomal components to overcome challenges of yield, scalability, and immunogenicity, enabling customizable and reproducible drug carriers. This chapter comprehensively reviews the design principles, fabrication methods, and functionalization techniques of exosome-mimetic nanocarriers, emphasizing their advantages in precision oncology. Mechanistic insights into cellular uptake, endosomal escape, and tumor targeting are comprehensive alongside preclinical studies demonstrating enhanced antitumor efficacy and safety profiles. Furthermore, the chapter discusses translational hurdles, including standardization, large-scale production, and regulatory considerations. Integration with emerging artificial intelligence tools and multiomics theranostics presents future opportunities for optimizing nanocarrier design, patient stratification, and treatment monitoring. Overall, exosome-mimetic nanocarriers represent a transformative strategy in nanomedicine, poised to revolutionize intracellular drug delivery and enable precision personalized therapy in breast cancer and beyond.
Keywords: Exosome, breast cancer, exosome-biomimetic nanocarriers, intracellular drug delivery, cargo loading, targeted therapy.
Keywords:
Exosome, breast cancer, exosome-biomimetic nanocarriers, intracellular drug delivery, cargo loading, targeted therapyDOI
https://doi.org/10.22270/jddt.v16i7.7891References
1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May 4;74(3):229-63. https://doi.org/10.3322/caac.21834 PMid:38572751
2. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024 Jan 17;74(1):12-49. https://doi.org/10.3322/caac.21820 PMid:38230766
3. Menon G, Alkabban FM, Ferguson T. Breast Cancer. 2025.
4. Zhang L, Yu D. Exosomes in cancer development, metastasis, and immunity. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2019 Apr;1871(2):455-68. https://doi.org/10.1016/j.bbcan.2019.04.004 PMid:31047959 PMCid:PMC6542596
5. Kalluri R, LeBleu VS. The biology , function , and biomedical applications of exosomes. Science (1979). 2020 Feb 7;367(6478). https://doi.org/10.1126/science.aau6977 PMid:32029601 PMCid:PMC7717626
6. Pfitzner AK, Mercier V, Jiang X, Moser von Filseck J, Baum B, Šarić A, et al. An ESCRT-III Polymerization Sequence Drives Membrane Deformation and Fission. Cell. 2020 Sep;182(5):1140-1155.e18. https://doi.org/10.1016/j.cell.2020.07.021 PMid:32814015 PMCid:PMC7479521
7. Vietri M, Radulovic M, Stenmark H. The many functions of ESCRTs. Nat Rev Mol Cell Biol. 2020 Jan 8;21(1):25-42. https://doi.org/10.1038/s41580-019-0177-4 PMid:31705132
8. Jeppesen DK, Fenix AM, Franklin JL, Higginbotham JN, Zhang Q, Zimmerman LJ, et al. Reassessment of Exosome Composition. Cell. 2019 Apr;177(2):428-445.e18. https://doi.org/10.1016/j.cell.2019.02.029 PMid:30951670 PMCid:PMC6664447
9. Qian D, Li J, Huang M, Cui Q, Liu X, Sun K. Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy. Biomedicine & Pharmacotherapy. 2023 Jun;162:114685. https://doi.org/10.1016/j.biopha.2023.114685 PMid:37058818
10. Jin X, Zhang J, Zhang Y, He J, Wang M, Hei Y, et al. Different origin-derived exosomes and their clinical advantages in cancer therapy. Front Immunol. 2024 Jun 27;15. https://doi.org/10.3389/fimmu.2024.1401852 PMid:38994350 PMCid:PMC11236555
11. Khattab AT, El-Keey MM, Beltagy DM, Salem MM. Revolutionizing Breast Cancer Treatment: Harnessing Ehrlich Ascites Carcinoma Model, Cancer Metabolism, and Nanotechnology-Enhanced Chemotherapy for Improved Patient Outcomes. Cell Biochem Biophys. 2025 Oct 31; https://doi.org/10.1007/s12013-025-01929-6 PMid:41171579
12. Rech J, Getinger-Panek A, Gałka S, Bednarek I. Origin and Composition of Exosomes as Crucial Factors in Designing Drug Delivery Systems. Applied Sciences. 2022 Nov 30;12(23):12259. https://doi.org/10.3390/app122312259
13. Zhang M, Viennois E, Prasad M, Zhang Y, Wang L, Zhang Z, et al. Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer. Biomaterials. 2016 Sep;101:321-40. https://doi.org/10.1016/j.biomaterials.2016.06.018 PMid:27318094 PMCid:PMC4921206
14. Li J, Wang J, Chen Z. Emerging role of exosomes in cancer therapy: progress and challenges. Mol Cancer. 2025 Jan 13;24(1):13. https://doi.org/10.1186/s12943-024-02215-4 PMid:39806451 PMCid:PMC11727182
15. Mukerjee N, Bhattacharya A, Maitra S, Kaur M, Ganesan S, Mishra S, et al. Exosome isolation and characterization for advanced diagnostic and therapeutic applications. Mater Today Bio. 2025 Apr;31:101613. https://doi.org/10.1016/j.mtbio.2025.101613 PMid:40161926 PMCid:PMC11950786
16. Maji S, Chaudhary P, Akopova I, Nguyen PM, Hare RJ, Gryczynski I, et al. Exosomal Annexin II Promotes Angiogenesis and Breast Cancer Metastasis. Molecular Cancer Research. 2017 Jan 1;15(1):93-105. https://doi.org/10.1158/1541-7786.MCR-16-0163 PMid:27760843 PMCid:PMC5215956
17. Chaudhary P, Gibbs LD, Maji S, Lewis CM, Suzuki S, Vishwanatha JK. Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis. Breast Cancer Research. 2020 Dec 28;22(1):11. https://doi.org/10.1186/s13058-020-1251-8 PMid:31992335 PMCid:PMC6986157
18. Wang Y, Ma Q, Wang T, Xing J, Li Q, Wang D, et al. The involvement and application potential of exosomes in breast cancer immunotherapy. Front Immunol. 2024 May 21;15. https://doi.org/10.3389/fimmu.2024.1384946 PMid:38835784 PMCid:PMC11148227
19. Zablon FM, Desai P, Dellinger K, Aravamudhan S. Cellular and Exosomal MicroRNAs: Emerging Clinical Relevance as Targets for Breast Cancer Diagnosis and Prognosis. Adv Biol. 2024 Apr 22;8(4). https://doi.org/10.1002/adbi.202300532 PMid:38258348 PMCid:PMC11198028
20. Kim MS, Haney MJ, Zhao Y, Mahajan V, Deygen I, Klyachko NL, et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine. 2016 Apr;12(3):655-64. https://doi.org/10.1016/j.nano.2015.10.012 PMid:26586551 PMCid:PMC4809755
21. Kim OY, Lee J, Gho YS. Extracellular vesicle mimetics: Novel alternatives to extracellular vesicle-based theranostics, drug delivery, and vaccines. Semin Cell Dev Biol. 2017 Jul;67:74-82. https://doi.org/10.1016/j.semcdb.2016.12.001 PMid:27916566
22. Antimisiaris SG, Mourtas S, Marazioti A. Exosomes and Exosome-Inspired Vesicles for Targeted Drug Delivery. Pharmaceutics. 2018 Nov 6;10(4):218. https://doi.org/10.3390/pharmaceutics10040218 PMid:30404188 PMCid:PMC6321407
23. Pascucci L, Coccè V, Bonomi A, Ami D, Ceccarelli P, Ciusani E, et al. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: A new approach for drug delivery. Journal of Controlled Release. 2014 Oct;192:262-70. https://doi.org/10.1016/j.jconrel.2014.07.042 PMid:25084218
24. Pascucci L, Coccè V, Bonomi A, Ami D, Ceccarelli P, Ciusani E, et al. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: A new approach for drug delivery. Journal of Controlled Release. 2014 Oct;192:262-70. https://doi.org/10.1016/j.jconrel.2014.07.042 PMid:25084218
25. Zhang Y, Liu Q, Zhang X, Huang H, Tang S, Chai Y, et al. Recent advances in exosome-mediated nucleic acid delivery for cancer therapy. J Nanobiotechnology. 2022 Jun 14;20(1):279. https://doi.org/10.1186/s12951-022-01472-z PMid:35701788 PMCid:PMC9194774
26. Zeng H, Guo S, Ren X, Wu Z, Liu S, Yao X. Current Strategies for Exosome Cargo Loading and Targeting Delivery. Cells. 2023 May 17;12(10):1416. https://doi.org/10.3390/cells12101416 PMid:37408250 PMCid:PMC10216928
27. Salunkhe S, Dheeraj, Basak M, Chitkara D, Mittal A. Surface functionalization of exosomes for target-specific delivery and in vivo imaging & tracking: Strategies and significance. Journal of Controlled Release. 2020 Oct;326:599-614. https://doi.org/10.1016/j.jconrel.2020.07.042 PMid:32730952
28. Gomari H, Forouzandeh Moghadam M, Soleimani M. Targeted cancer therapy using engineered exosome as a natural drug delivery vehicle. Onco Targets Ther. 2018 Sep;Volume 11:5753-62. https://doi.org/10.2147/OTT.S173110 PMid:30254468 PMCid:PMC6140699
29. Vakhshiteh F, Rahmani S, Ostad SN, Madjd Z, Dinarvand R, Atyabi F. Exosomes derived from miR-34a-overexpressing mesenchymal stem cells inhibit in vitro tumor growth: A new approach for drug delivery. Life Sci. 2021 Feb;266:118871. https://doi.org/10.1016/j.lfs.2020.118871 PMid:33309716
30. Yang P, Cao X, Cai H, Feng P, Chen X, Zhu Y, et al. The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth. Cell Immunol. 2021 Feb;360:104262. https://doi.org/10.1016/j.cellimm.2020.104262 PMid:33373818
31. Shojaei S, Hashemi SM, Ghanbarian H, Sharifi K, Salehi M, Mohammadi-Yeganeh S. Delivery of miR-381-3p Mimic by Mesenchymal Stem Cell-Derived Exosomes Inhibits Triple Negative Breast Cancer Aggressiveness; an In Vitro Study. Stem Cell Rev Rep. 2021 Jun 6;17(3):1027-38. https://doi.org/10.1007/s12015-020-10089-4 PMid:33410095
32. Lopes D, Lopes J, Pereira-Silva M, Peixoto D, Rabiee N, Veiga F, et al. Bioengineered exosomal-membrane-camouflaged abiotic nanocarriers: neurodegenerative diseases, tissue engineering and regenerative medicine. Mil Med Res. 2023 Apr 27;10(1):19. https://doi.org/10.1186/s40779-023-00453-z PMid:37101293 PMCid:PMC10134679
33. Palakurthi SS, Shah B, Kapre S, Charbe N, Immanuel S, Pasham S, et al. A comprehensive review of challenges and advances in exosome-based drug delivery systems. Nanoscale Adv. 2024;6(23):5803-26. https://doi.org/10.1039/D4NA00501E PMid:39484149 PMCid:PMC11523810
34. Li YJ, Wu JY, Liu J, Xu W, Qiu X, Huang S, et al. Artificial exosomes for translational nanomedicine. J Nanobiotechnology. 2021 Aug 12;19(1):242. https://doi.org/10.1186/s12951-021-00986-2 PMid:34384440 PMCid:PMC8359033
35. Ravar F, Saadat E, Gholami M, Dehghankelishadi P, Mahdavi M, Azami S, et al. Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation. Journal of Controlled Release. 2016 May;229:10-22. https://doi.org/10.1016/j.jconrel.2016.03.012 PMid:26968799
36. Xu X, Xu L, Wen C, Xia J, Zhang Y, Liang Y. Programming assembly of biomimetic exosomes: An emerging theranostic nanomedicine platform. Mater Today Bio. 2023 Oct;22:100760. https://doi.org/10.1016/j.mtbio.2023.100760 PMid:37636982 PMCid:PMC10450992
37. Jiang W, Ma P, Deng L, Liu Z, Wang X, Liu X, et al. Hepatitis A virus structural protein pX interacts with ALIX and promotes the secretion of virions and foreign proteins through exosome‐like vesicles. J Extracell Vesicles. 2020 Sep 22;9(1). https://doi.org/10.1080/20013078.2020.1716513 PMid:32082513 PMCid:PMC7006762
38. Paul S, Bhagat S, Dash L, Mohapatra H Das, Jena S, Verma SK, et al. ExoDS: a versatile exosome-based drug delivery platform to target cancer cells and cancer stem cells. Front Bioeng Biotechnol. 2024 Jun 5;12. https://doi.org/10.3389/fbioe.2024.1362681 PMid:38903193 PMCid:PMC11188490
39. Liu JJJ, Liu D, To SKY, Wong AST. Exosomes in cancer nanomedicine: biotechnological advancements and innovations. Mol Cancer. 2025 Jun 7;24(1):166. https://doi.org/10.1186/s12943-025-02372-0 PMid:40481526 PMCid:PMC12144782
40. Li L, Wang F, Zhu D, Hu S, Cheng K, Li Z. Engineering exosomes and exosome-like nanovesicles for improving tissue targeting and retention. Fundamental Research. 2025 Mar;5(2):851-67. https://doi.org/10.1016/j.fmre.2024.03.025 PMid:40242543 PMCid:PMC11997600
41. Galardi A, Fogazzi V, Tottone C, Giussani M, Pupa SM, Cosentino G, et al. Small extracellular vesicles: messengers at the service of breast cancer agenda in the primary and distant microenvironments. Journal of Experimental & Clinical Cancer Research. 2025 Jul 21;44(1):216. https://doi.org/10.1186/s13046-025-03471-y PMid:40691627 PMCid:PMC12278669
42. Díaz J, Mendoza P, Ortiz R, Díaz N, Leyton L, Stupack D, et al. Rab5 is required for Caveolin-1-enhanced Rac1 activation, migration and invasion of metastatic cancer cells. J Cell Sci. 2014 Jan 1; https://doi.org/10.1242/jcs.141689 PMid:24659799 PMCid:PMC4074264
43. Khan I, Steeg PS. Endocytosis: a pivotal pathway for regulating metastasis. Br J Cancer. 2021 Jan 5;124(1):66-75. https://doi.org/10.1038/s41416-020-01179-8 PMid:33262521 PMCid:PMC7782782
44. Li JJ, Tsang JY, Tse GM. Tumor Microenvironment in Breast Cancer-Updates on Therapeutic Implications and Pathologic Assessment. Cancers (Basel). 2021 Aug 23;13(16):4233. https://doi.org/10.3390/cancers13164233 PMid:34439387 PMCid:PMC8394502
45. Barker HE, Paget JTE, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015 Jul 24;15(7):409-25. https://doi.org/10.1038/nrc3958 PMid:26105538 PMCid:PMC4896389
46. Niveria K, Yadav M, Dangi K, Verma AK. Overcoming challenges to enable targeting of metastatic breast cancer tumour microenvironment with nano-therapeutics: Current status and future perspectives. OpenNano. 2022 Nov;8:100083. https://doi.org/10.1016/j.onano.2022.100083
47. Sarkar R, Biswas S, Ghosh R, Samanta P, Pakhira S, Mondal M, et al. Exosome-sheathed porous silica nanoparticle-mediated co-delivery of 3,3′-diindolylmethane and doxorubicin attenuates cancer stem cell-driven EMT in triple negative breast cancer. J Nanobiotechnology. 2024 May 25;22(1):285. https://doi.org/10.1186/s12951-024-02518-0 PMid:38796426 PMCid:PMC11127288
48. Wang X, Zhong W, Bu J, Li Y, Li R, Nie R, et al. Exosomal protein CD82 as a diagnostic biomarker for precision medicine for breast cancer. Mol Carcinog. 2019 May 20;58(5):674-85. https://doi.org/10.1002/mc.22960 PMid:30604894 PMCid:PMC10670968
49. Ando W, Kikuchi K, Uematsu T, Yokomori H, Takaki T, Sogabe M, et al. Novel breast cancer screening: combined expression of miR-21 and MMP-1 in urinary exosomes detects 95% of breast cancer without metastasis. Sci Rep. 2019 Sep 19;9(1):13595. https://doi.org/10.1038/s41598-019-50084-5 PMid:31537868 PMCid:PMC6753125
50. Rupp AK, Rupp C, Keller S, Brase JC, Ehehalt R, Fogel M, et al. Loss of EpCAM expression in breast cancer derived serum exosomes: Role of proteolytic cleavage. Gynecol Oncol. 2011 Aug;122(2):437-46. https://doi.org/10.1016/j.ygyno.2011.04.035 PMid:21601258
51. Moon PG, Lee JE, Cho YE, Lee SJ, Jung JH, Chae YS, et al. Identification of Developmental Endothelial Locus-1 on Circulating Extracellular Vesicles as a Novel Biomarker for Early Breast Cancer Detection. Clinical Cancer Research. 2016 Apr 1;22(7):1757-66. https://doi.org/10.1158/1078-0432.CCR-15-0654 PMid:26603257
52. Khan S, Bennit HF, Turay D, Perez M, Mirshahidi S, Yuan Y, et al. Early diagnostic value of survivin and its alternative splice variants in breast cancer. BMC Cancer. 2014 Dec 12;14(1):176. https://doi.org/10.1186/1471-2407-14-176 PMid:24620748 PMCid:PMC3995700
53. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015 Jul 9;523(7559):177-82. https://doi.org/10.1038/nature14581 PMid:26106858 PMCid:PMC4825698
54. Hannafon BN, Trigoso YD, Calloway CL, Zhao YD, Lum DH, Welm AL, et al. Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Research. 2016 Dec 8;18(1):90. https://doi.org/10.1186/s13058-016-0753-x PMid:27608715 PMCid:PMC5016889
55. Gonzalez-Villasana V, Rashed MH, Gonzalez-Cantú Y, Bayraktar R, Menchaca-Arredondo JL, Vazquez-Guillen JM, et al. Presence of Circulating miR-145, miR-155, and miR-382 in Exosomes Isolated from Serum of Breast Cancer Patients and Healthy Donors. Dis Markers. 2019 Feb 12;2019:1-9. https://doi.org/10.1155/2019/6852917 PMid:30891102 PMCid:PMC6390256
56. Eichelser C, Stückrath I, Müller V, Milde-Langosch K, Wikman H, Pantel K, et al. Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget. 2014 Oct 30;5(20):9650-63. https://doi.org/10.18632/oncotarget.2520 PMid:25333260 PMCid:PMC4259427
57. Ni Q, Stevic I, Pan C, Müller V, Oliveira-Ferrer L, Pantel K, et al. Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients. Sci Rep. 2018 Aug 28;8(1):12974. https://doi.org/10.1038/s41598-018-31108-y PMid:30154547 PMCid:PMC6113263
58. Vázquez-Ríos AJ, Molina-Crespo Á, Bouzo BL, López-López R, Moreno-Bueno G, de la Fuente M. Exosome-mimetic nanoplatforms for targeted cancer drug delivery. J Nanobiotechnology. 2019 Dec 18;17(1):85. https://doi.org/10.1186/s12951-019-0517-8 PMid:31319859 PMCid:PMC6637649
59. Zhang X, Sathiyaseelan A, Jin T, Wang MH. Synthesis of folic acid-tailored chitosan-coated exosomes for targeted delivery of 5-fluorouracil to triple-negative breast cancer cells. Colloids Surf B Biointerfaces. 2025 Sep;253:114737. https://doi.org/10.1016/j.colsurfb.2025.114737 PMid:40328147
60. Uslu D, Abas BI, Demirbolat GM, Cevik O. Effect of platelet exosomes loaded with doxorubicin as a targeted therapy on triple-negative breast cancer cells. Mol Divers. 2024 Apr 28;28(2):449-60. https://doi.org/10.1007/s11030-022-10591-6 PMid:36576666
61. Tran NH, Nguyen DD, Nguyen NM, Tran C, Nguyen Thi NT, Ho DT, et al. Dual-Targeting Exosomes for Improved Drug Delivery in Breast Cancer. Nanomedicine. 2023 Mar 17;18(7):599-611. https://doi.org/10.2217/nnm-2022-0328 PMid:37194929
62. Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ, et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 2014 Feb;35(7):2383-90. https://doi.org/10.1016/j.biomaterials.2013.11.083 PMid:24345736 PMCid:PMC13223469
63. Wan Y, Wang L, Zhu C, Zheng Q, Wang G, Tong J, et al. Aptamer-Conjugated Extracellular Nanovesicles for Targeted Drug Delivery. Cancer Res. 2018 Feb 1;78(3):798-808. https://doi.org/10.1158/0008-5472.CAN-17-2880 PMid:29217761 PMCid:PMC5811376
64. Cao Y, Wu T, Zhang K, Meng X, Dai W, Wang D, et al. Engineered Exosome-Mediated Near-Infrared-II Region V 2 C Quantum Dot Delivery for Nucleus-Target Low-Temperature Photothermal Therapy. ACS Nano. 2019 Jan 29;acsnano.8b07224. https://doi.org/10.1021/acsnano.8b07224 PMid:30677286
65. Ohno S ichiro, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuyama N, et al. Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells. Molecular Therapy. 2013 Jan;21(1):185-91. https://doi.org/10.1038/mt.2012.180 PMid:23032975 PMCid:PMC3538304
66. Liu J, Zhu S, Tang W, Huang Q, Mei Y, Yang H. Exosomes from tamoxifen-resistant breast cancer cells transmit drug resistance partly by delivering miR-9-5p. Cancer Cell Int. 2021 Dec 15;21(1):55. https://doi.org/10.1186/s12935-020-01659-0 PMid:33451320 PMCid:PMC7809732
67. Limoni SK, Moghadam MF, Moazzeni SM, Gomari H, Salimi F. Engineered Exosomes for Targeted Transfer of siRNA to HER2 Positive Breast Cancer Cells. Appl Biochem Biotechnol. 2019 Jan 28;187(1):352-64. https://doi.org/10.1007/s12010-018-2813-4 PMid:29951961
68. Wang JH, Forterre A V., Zhao J, Frimannsson DO, Delcayre A, Antes TJ, et al. Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation. Mol Cancer Ther. 2018 May 1;17(5):1133-42. https://doi.org/10.1158/1535-7163.MCT-17-0827 PMid:29483213 PMCid:PMC5932266
69. Si Y, Chen K, Ngo HG, Guan JS, Totoro A, Zhou Z, et al. Targeted EV to Deliver Chemotherapy to Treat Triple-Negative Breast Cancers. Pharmaceutics. 2022 Jan 7;14(1):146. https://doi.org/10.3390/pharmaceutics14010146 PMid:35057042 PMCid:PMC8781632
70. Huang L, Rong Y, Tang X, Yi K, Qi P, Hou J, et al. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer. Mol Cancer. 2022 Dec 11;21(1):45. https://doi.org/10.1186/s12943-022-01515-x PMid:35148751 PMCid:PMC8831689
71. Chen Q, Che C, Liu J, Gong Z, Si M, Yang S, et al. Construction of an exosome-functionalized graphene oxide based composite bionic smart drug delivery system and its anticancer activity. Nanotechnology. 2022 Apr 23;33(17):175101. https://doi.org/10.1088/1361-6528/ac49bf PMid:35008083
72. Ghavami M, Vraka C, Hubert V, Schachner H, Bamminger K, Hacker M, et al. Radiolabeled HER2-Directed Exosomes Exhibit Improved Cell Targeting and Specificity. Nanomedicine. 2021 Mar 17;16(7):553-67. https://doi.org/10.2217/nnm-2020-0408 PMid:33728944
73. Wang K, Ye H, Zhang X, Wang X, Yang B, Luo C, et al. An exosome-like programmable-bioactivating paclitaxel prodrug nanoplatform for enhanced breast cancer metastasis inhibition. Biomaterials. 2020 Oct;257:120224. https://doi.org/10.1016/j.biomaterials.2020.120224 PMid:32736255
74. Li S, Wu Y, Ding F, Yang J, Li J, Gao X, et al. Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer. Nanoscale. 2020;12(19):10854-62. https://doi.org/10.1039/D0NR00523A PMid:32396590
75. Zhao L, Gu C, Gan Y, Shao L, Chen H, Zhu H. Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis. Journal of Controlled Release. 2020 Feb;318:1-15. https://doi.org/10.1016/j.jconrel.2019.12.005 PMid:31830541
76. Tian R, Wang Z, Niu R, Wang H, Guan W, Chang J. Tumor Exosome Mimicking Nanoparticles for Tumor Combinatorial Chemo-Photothermal Therapy. Front Bioeng Biotechnol. 2020 Aug 31;8. https://doi.org/10.3389/fbioe.2020.01010 PMid:32984284 PMCid:PMC7487365
77. Badawy AA, El-Magd MA, AlSadrah SA. Therapeutic Effect of Camel Milk and Its Exosomes on MCF7 Cells In Vitro and In Vivo. Integr Cancer Ther. 2018 Dec 10;17(4):1235-46. https://doi.org/10.1177/1534735418786000 PMid:29986606 PMCid:PMC6247558
78. Yang D, Zhang L, Ni J, Ding Y, Razzaq A, Khan ZU, et al. Stimuli-sensitive biomimetic nanoparticles for the inhibition of breast cancer recurrence and pulmonary metastasis. Int J Pharm X. 2024 Jun;7:100252. https://doi.org/10.1016/j.ijpx.2024.100252 PMid:38766479 PMCid:PMC11101870
79. Marshall SK, Angsantikul P, Pang Z, Nasongkla N, Hussen RSD, Thamphiwatana SD. Biomimetic Targeted Theranostic Nanoparticles for Breast Cancer Treatment. Molecules. 2022 Oct 1;27(19):6473. https://doi.org/10.3390/molecules27196473 PMid:36235009 PMCid:PMC9571674
80. Shtam T, Naryzhny S, Samsonov R, Karasik D, Mizgirev I, Kopylov A, et al. Plasma exosomes stimulate breast cancer metastasis through surface interactions and activation of FAK signaling. Breast Cancer Res Treat. 2019 Feb 27;174(1):129-41. https://doi.org/10.1007/s10549-018-5043-0 PMid:30484103
81. Baucum M, Khojandi A, Vasudevan R. Improving Deep Reinforcement Learning With Transitional Variational Autoencoders: A Healthcare Application. IEEE J Biomed Health Inform. 2021 Jun;25(6):2273-80. https://doi.org/10.1109/JBHI.2020.3027443 PMid:32991294
82. Mienye ID, Swart TG, Obaido G, Jordan M, Ilono P. Deep Convolutional Neural Networks: A Comprehensive Review. 2024. https://doi.org/10.20944/preprints202408.1288.v1
83. Shirzad M, Shaban M, Mohammadzadeh V, Rahdar A, Fathi-karkan S, Hoseini ZS, et al. Artificial Intelligence-Assisted Design of Nanomedicines for Breast Cancer Diagnosis and Therapy: Advances, Challenges, and Future Directions. Bionanoscience. 2025 Sep 21;15(3):354. https://doi.org/10.1007/s12668-025-01980-w
84. Kimiz-Gebologlu I, Oncel SS. Exosomes: Large-scale production, isolation, drug loading efficiency, and biodistribution and uptake. Journal of Controlled Release. 2022 Jul;347:533-43. https://doi.org/10.1016/j.jconrel.2022.05.027 PMid:35597405
85. Liu JJJ, Liu D, To SKY, Wong AST. Exosomes in cancer nanomedicine: biotechnological advancements and innovations. Mol Cancer. 2025 Jun 7;24(1):166. https://doi.org/10.1186/s12943-025-02372-0 PMid:40481526 PMCid:PMC12144782
Published
Abstract Display: 0 
PDF Downloads: 0 PDF Downloads: 0 How to Cite
Issue
Section
Copyright (c) 2026 Tapaskumar Mukeshkumar Shah
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.